Subscribe
oktay-ortakcioglu
oktay-ortakcioglu / iStockphoto.com
18 April 2018Asia-Pacific

China releases measures to boost pharma IP protection

China’s government has announced a series of measures to increase the country’s importation of drugs, including enhanced IP protection in the pharmaceutical industry.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia-Pacific
China to slash tax for generic makers to 15%
9 April 2018   China’s government has announced plans to implement preferential tax rates to generic drug makers in a bid to encourage the manufacturing of generics.


Editor's picks

A step too far? Why Stewart’s approach is dividing opinion
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

Editor's picks

Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025

More on this story

Asia-Pacific
China to slash tax for generic makers to 15%
9 April 2018   China’s government has announced plans to implement preferential tax rates to generic drug makers in a bid to encourage the manufacturing of generics.

More on this story

Asia-Pacific
China to slash tax for generic makers to 15%
9 April 2018   China’s government has announced plans to implement preferential tax rates to generic drug makers in a bid to encourage the manufacturing of generics.

More features

WATCH: Policy direction—where are we now?
Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Boies Schiller Flexner adds three-strong litigation team
AstraZeneca forced to clarify deal terms in row with university
Novartis loses cancer drug patent following Teva challenge at EPO
A step too far? Why Stewart’s approach is dividing opinion